Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $5.10 for the company and are anticipating that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 120 out of 265 based on the ratings given to its competitors.
EPIX has been the topic of a number of research reports. Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a research note on Thursday, August 3rd. Bloom Burton reiterated a “buy” rating on shares of ESSA Pharma in a research note on Thursday, May 18th. ValuEngine lowered shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 7th. Finally, Zacks Investment Research upgraded shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 18th.
COPYRIGHT VIOLATION NOTICE: “ESSA Pharma Inc. (NASDAQ:EPIX) Given $5.10 Average Target Price by Analysts” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/19/essa-pharma-inc-nasdaqepix-given-5-10-average-target-price-by-analysts-updated.html.
ESSA Pharma (NASDAQ EPIX) traded up 13.1475% during midday trading on Tuesday, reaching $0.3451. 80,934 shares of the company’s stock were exchanged. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59. The stock’s market capitalization is $10.04 million. The stock’s 50-day moving average is $0.46 and its 200-day moving average is $1.73.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
